Radical Radiotherapy for Locally Advanced Cancer of Uterine Cervix.
- Author:
Jeung Eun LEE
1
;
Seung Jae HUH
;
Won PARK
;
Do Hoon LIM
;
Yong Chan AHN
;
Chang Soo PARK
;
Byoung Gie KIM
;
Duk Soo BAE
;
Je Ho LEE
;
Chong Taik PARK
;
Tae Jin KIM
;
Kyung Taek LIM
;
Hwan Wook CHUNG
;
Ki Heon LEE
;
Jae Uk SHIM
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. happylark@hanmir.com
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Advanced cancer of the uterine cervix;
High-dose rate brachytherapy
- MeSH:
Brachytherapy;
Cervix Uteri*;
Disease-Free Survival;
Drug Therapy;
Female;
Follow-Up Studies;
Fractures, Stress;
Humans;
Incidence;
Multivariate Analysis;
Pelvis;
Radiation Oncology;
Radiotherapy*;
Rectum;
Urinary Bladder
- From:Cancer Research and Treatment
2004;36(4):222-227
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was performed to evaluate the treatment results, prognostic factors and complication rates in patients with locally advanced cancer of uterine cervix after radiotherapy with high-dose rate (HDR) brachytherapy. MATERIALS AND METHODS: One hundred and twenty patients with a locally advanced (stages IIB~IVA according to FIGO classification) carcinoma of the uterine cervix were treated with radiotherapy at the Department of Radiation Oncology, Samsung Medical Center between September 1994 and December 2001. The median age of the patients was 61 years (range 29 to 81). Sixty-one, 56 and 3 patients had FIGO stage IIB, III, and IV diseases, respectively. All patients were given external beam radiotherapy over the whole pelvis (median 50.4 Gy) and HDR intracavitary brachytherapy, with a median of 4 Gy per fraction, to point A. Twenty-one patients received chemotherapy, of which 13 and 21 received neoadjuvant chemotherapy and concurrent chemotherapy, respectively, during the first and fourth weeks of external beam radiotherapy. The chemotherapy was not randomly assigned and the median follow-up time was 28.5 months (range: 6~100 months). RESULTS: The three- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 64.4 and 57.0%, and 63.7 and 60.2%, respectively. The 5-year OS and DFS rates of the patients at stages IIB, III and IV were 602, 57.9 and 33.3%, and 57.4, 65.4 and 33.3%, respectively. Univariate analysis indicated that the FIGO stage, overall treatment time (OTT) and treatment response were significant variables for the OS (p=0.035, p=0.0649 and p=0.0009) and of the DFS (p=0.0009, p=0.0359 and p=0.0363). Multivariate analysis showed that the treatment response was the only significant variable for the OS (p=0.0018) and OTT for the DFS (p=0.0360). The overall incidence of late complications in the rectum and bladder were 11.7 and 6.7%, respectively. In addition, insufficiency fractures were observed in 7 patients (5.8%). CONCLUSION: The results of this study suggest that radical radiotherapy with HDR brachytherapy was appropriate for the treatment of locally advanced uterine cervix cancer. Also, the response after treatment and OTT are significant prognostic factors.
